PMID- 30309369 OWN - NLM STAT- MEDLINE DCOM- 20190423 LR - 20201218 IS - 1476-4598 (Electronic) IS - 1476-4598 (Linking) VI - 17 IP - 1 DP - 2018 Oct 11 TI - Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis. PG - 148 LID - 10.1186/s12943-018-0891-0 [doi] LID - 148 AB - Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer related to asbestos exposure. The discovery of soluble biomarkers with diagnostic/prognostic and/or therapeutic properties would improve therapeutic care of MPM patients. Currently, soluble biomarkers described present weaknesses preventing their use in clinic. This study aimed at evaluating brain-derived neurotrophic factor (BDNF), we previously identified using transcriptomic approach, in MPM. We observed that high BDNF expression, at the mRNA level in tumors or at the protein level in pleural effusions (PE), was a specific hallmark of MPM samples. This protein presented significant but limited diagnostic properties (area under the curve (AUC) = 0.6972, p < 0.0001). Interestingly, high BDNF gene expression and PE concentration were predictive of shorter MPM patient survival (13.0 vs 8.3 months, p < 0.0001, in PE). Finally, BDNF did not affect MPM cell oncogenic properties but was implicated in PE-induced angiogenesis. In conclusion, BDNF appears to be a new interesting biomarker for MPM and could also be a new therapeutic target regarding its implication in angiogenesis. FAU - Smeele, Patrick AU - Smeele P AD - CRCINA, INSERM, Universite d'Angers, Universite de Nantes, Nantes, France. FAU - d'Almeida, Senan Mickael AU - d'Almeida SM AD - CRCINA, INSERM, Universite d'Angers, Universite de Nantes, Nantes, France. AD - Massachusetts General Hospital, Harvard Medical School, Boston, USA. FAU - Meiller, Clement AU - Meiller C AD - INSERM, UMR-1162, Functional Genomics of Solid Tumors, Universite Paris Descartes, Universite Paris Diderot, Universite Paris 13, Paris, France. FAU - Chene, Anne-Laure AU - Chene AL AD - CRCINA, INSERM, Universite d'Angers, Universite de Nantes, Nantes, France. AD - Service d'Oncologie Medicale Thoracique et Digestive, Hopital Laennec, CHU de Nantes, Nantes, France. FAU - Liddell, Charly AU - Liddell C AD - CRCINA, INSERM, Universite d'Angers, Universite de Nantes, Nantes, France. AD - Service d'Anatomie Pathologique, Hopital Laennec, CHU de Nantes, Nantes, France. FAU - Cellerin, Laurent AU - Cellerin L AD - CRCINA, INSERM, Universite d'Angers, Universite de Nantes, Nantes, France. AD - Service d'Oncologie Medicale Thoracique et Digestive, Hopital Laennec, CHU de Nantes, Nantes, France. FAU - Montagne, Francois AU - Montagne F AD - INSERM, UMR-1162, Functional Genomics of Solid Tumors, Universite Paris Descartes, Universite Paris Diderot, Universite Paris 13, Paris, France. AD - Service de Chirurgie Thoracique, Hopital Calmette, CHRU Lille, Lille, France. FAU - Deshayes, Sophie AU - Deshayes S AD - CRCINA, INSERM, Universite d'Angers, Universite de Nantes, Nantes, France. FAU - Benziane, Sarah AU - Benziane S AD - Pulmonary and Thoracic Oncology, CHU de Lille, Univ. Lille, INSERM U1019, CIIL Institut Pasteur de Lille, F59000, Lille, France. AD - French National Network of Clinical Expert Centers for Malignant Pleural Mesothelioma Management (MESOCLIN), F59000, Lille, France. FAU - Copin, Marie-Christine AU - Copin MC AD - Univ. Lille, CHU Lille, Institut de Pathologie et Tumorotheque du C2RC, Avenue Oscar Lambret, F-59000, Lille, France. FAU - Hofman, Paul AU - Hofman P AD - Laboratory of Clinical and Experimental Pathology and Hospital-related Biobank (BB-0033-00025), University Cote d'Azur, Nice, France. FAU - Le Pimpec-Barthes, Francoise AU - Le Pimpec-Barthes F AD - INSERM, UMR-1162, Functional Genomics of Solid Tumors, Universite Paris Descartes, Universite Paris Diderot, Universite Paris 13, Paris, France. AD - Departement de Chirurgie Thoracique et Transplantation pulmonaire, Hopital Europeen Georges Pompidou, Paris, France. FAU - Porte, Henri AU - Porte H AD - Service de Chirurgie Thoracique, Hopital Calmette, CHRU Lille, Lille, France. FAU - Scherpereel, Arnaud AU - Scherpereel A AD - Pulmonary and Thoracic Oncology, CHU de Lille, Univ. Lille, INSERM U1019, CIIL Institut Pasteur de Lille, F59000, Lille, France. AD - French National Network of Clinical Expert Centers for Malignant Pleural Mesothelioma Management (MESOCLIN), F59000, Lille, France. FAU - Gregoire, Marc AU - Gregoire M AD - CRCINA, INSERM, Universite d'Angers, Universite de Nantes, Nantes, France. FAU - Jean, Didier AU - Jean D AD - INSERM, UMR-1162, Functional Genomics of Solid Tumors, Universite Paris Descartes, Universite Paris Diderot, Universite Paris 13, Paris, France. FAU - Blanquart, Christophe AU - Blanquart C AUID- ORCID: 0000-0002-0917-3747 AD - CRCINA, INSERM, Universite d'Angers, Universite de Nantes, Nantes, France. christophe.blanquart@inserm.fr. LA - eng PT - Letter PT - Research Support, Non-U.S. Gov't DEP - 20181011 PL - England TA - Mol Cancer JT - Molecular cancer JID - 101147698 RN - 0 (Biomarkers, Tumor) RN - 0 (Brain-Derived Neurotrophic Factor) RN - 0 (RNA, Messenger) SB - IM MH - Biomarkers, Tumor MH - Brain-Derived Neurotrophic Factor/*blood/genetics MH - Gene Expression MH - Humans MH - Lung Neoplasms/*blood/genetics/mortality/*pathology MH - Mesothelioma/*blood/genetics/mortality/*pathology MH - Mesothelioma, Malignant MH - Neovascularization, Pathologic/*blood MH - Pleural Effusion, Malignant/genetics/metabolism MH - Pleural Neoplasms/*blood/genetics/mortality/*pathology MH - Prognosis MH - RNA, Messenger/genetics MH - ROC Curve PMC - PMC6180566 OTO - NOTNLM OT - Angiogenesis OT - BDNF OT - Biomarkers OT - Mesothelioma OT - Pleural effusions COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: All recruited patients gave signed, informed consent. All the collected samples and the associated clinical information were registered in database (DC-2011-1399 and DC-2013-1963) validated by the French research ministry. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interest. PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. EDAT- 2018/10/13 06:00 MHDA- 2019/04/24 06:00 PMCR- 2018/10/11 CRDT- 2018/10/13 06:00 PHST- 2018/03/30 00:00 [received] PHST- 2018/09/14 00:00 [accepted] PHST- 2018/10/13 06:00 [entrez] PHST- 2018/10/13 06:00 [pubmed] PHST- 2019/04/24 06:00 [medline] PHST- 2018/10/11 00:00 [pmc-release] AID - 10.1186/s12943-018-0891-0 [pii] AID - 891 [pii] AID - 10.1186/s12943-018-0891-0 [doi] PST - epublish SO - Mol Cancer. 2018 Oct 11;17(1):148. doi: 10.1186/s12943-018-0891-0.